The ASCU/LSIL Triage Study for Cervical Cancer: ALTS study

ALTS 是一项旨在寻找最佳方法来帮助女性及其医生决定如何处理轻度异常且非常常见的子宫颈抹片检查结果（称为 ASCUS 和 LSIL）的研究。美国每年约有 300 万女性被诊断患有 ASCUS 和 LSIL。 ALTS 由国家癌症研究所组织和资助，成员包括 5,000 多名女性。该试验于 1996 年 11 月开始，于 2000 年底结束。试验结果的数据分析正在进行中。 ASCUS 代表意义未明的非典型鳞状细胞，LSIL 代表低度鳞状上皮内病变。大多数这些轻微的异常现象无需治疗就会消失，但有些可能预示着癌前病变，或者罕见的癌症。 ALTS 研究了三种处理这些异常的方法： 立即阴道镜检查（放大观察和测试子宫颈） 重复巴氏试验 检测人乳头瘤病毒 (HPV)，这是一种与宫颈癌相关的感染

ALTS was a study undertaken to find the best way to help women and their doctors decide what to do about the mildly abnormal and very common Pap test results known as ASCUS and LSIL. About three million women in the United States are diagnosed with ASCUS and LSIL each year. Organized and funded by the National Cancer Institute, ALTS included more than 5,000 women. It began in November 1996 and concluded at the end of 2000. Data analysis of the trial's findings is ongoing. ASCUS stands for atypical squamous cells of undetermined significance and LSIL for low-grade squamous intraepithelial lesions. Most of these mild abnormalities will go away without treatment, but some may signal a precancerous condition or, rarely, cancer. ALTS looked at three ways to manage these abnormalities: immediate colposcopy (magnified viewing and testing of the cervix) repeat Pap tests testing for human papillomavirus (HPV), an infection linked to cervical cancer